Phase 1 B-cell Malignancies Clinical Trials
10 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–10 of 10 trials
Recruiting
Phase 1Phase 2
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
B-cell Malignancies
AstraZeneca174 enrolled30 locationsNCT06542250
Recruiting
Phase 1
IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies
Relapsed/Refractory B-cell Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology12 enrolled1 locationNCT07309900
Recruiting
Phase 1
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Relapsed or Refractory B-cell Malignancies
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.50 enrolled4 locationsNCT06980116
Recruiting
Phase 1
UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
Relapsed/Refractory B-cell Malignancies
Ubix Therapeutics, Inc.94 enrolled11 locationsNCT06590961
Recruiting
Phase 1
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Relapsed/Refractory B-cell Malignancies
Accutar Biotechnology Inc60 enrolled9 locationsNCT05780034
Recruiting
Phase 1Phase 2
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
B-cell Malignancies
Shenzhen Geno-Immune Medical Institute100 enrolled4 locationsNCT03125577
Recruiting
Phase 1Phase 2
A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
B-cell Malignancies
Shenzhen Geno-Immune Medical Institute200 enrolled2 locationsNCT03050190
Recruiting
Phase 1
The LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies
Relapsed/Refractory B-cell Malignancies
The First Affiliated Hospital with Nanjing Medical University30 enrolled6 locationsNCT07002112
Recruiting
Phase 1
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies
Mature B-cell Malignancies
InnoCare Pharma Inc.78 enrolled8 locationsNCT06351527
Recruiting
Phase 1
Evaluation of SYS6005 in Patients With Advanced Malignant Tumor
Solid TumorsB-cell Malignancies
CSPC Megalith Biopharmaceutical Co.,Ltd.132 enrolled1 locationNCT06958679